For more information

Contact:
Ericka R. Patrick, RN
341 Ponce de Leon Avenue
Atlanta, GA 30308
404.616.6313

Study Purpose:
The purpose of this study is to evaluate safety and to determine whether E/C/F/TAF STR plus Darunavir (DRV) is effective against HIV-1 in subjects on current antiretroviral regimens (ARV) in virologically suppressed, HIV-1 positive subjects.

Key requirements to be eligible for the study:
- 48 weeks on study
- ≥ 4mo suppressed on ARVs containing either DRV once a day or twice a day
- Have history of genotype resistance to at least three classes of ARV agents
- Are currently receiving Raltegravir, Elvitegravir, or Dolutegravir (50mg once daily only)
- Have HIV RNA <50 copies/mL

Study Treatment:
Subjects will be randomized in a 2 : 1 ratio to one of the two treatment arms

Arm 1: Elvitegravir 150mg/Cobicistat 150mg/Emtricitabine 200mg/Tenofovir Alafenamide 10mg (E/C/F/TAF) STR plus DRV 800mg once daily. Study medication will be provided for Arm 1

Arm 2: Subjects will remain on current, pre-existing ARV regimen